会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明授权
    • Wire configuration and method of making for an implantable medical apparatus
    • 电线配置和可植入医疗器械的制造方法
    • US08639352B2
    • 2014-01-28
    • US12419082
    • 2009-04-06
    • Ling WangBernard Q. Li
    • Ling WangBernard Q. Li
    • A61N1/04
    • A61N1/05A61N1/0472A61N1/0488A61N1/0551Y10T29/49002
    • A filar includes an inner conductive core that is formed of a low-resistivity material such as silver having a resistivity of less than 20 μΩ per centimeter. A conductive coil is provided around the core to form a filar. This coil is formed of a biocompatible alloy or super alloy having an ultimate tensile strength (UTS) of between 150 kilo pounds per square inch (ksi) and 280 ksi at room temperature. Examples of such alloys include CoCrMo, CoFeCrMo, and CoFeNiCrMo. In one specific embodiment, the alloy is MP35N (CoNiCrMo), which may be low-titanium (“low-ti”) MP35N. One or more such filars may be included within a wire. This wire may be carried by an implantable medical apparatus such as a lead, lead extension, or catheter. The wire may electrically couple elements such as connector electrodes to conducting electrodes or sensors.
    • 丝状物包括由诸如银的低电阻率材料形成的内导电芯,其电阻率小于每平方厘米20微米。 在芯周围设置导电线圈以形成丝状体。 该线圈由在室温下具有150千磅/平方英寸(ksi)和280ksi之间的极限拉伸强度(UTS)的生物相容性合金或超级合金形成。 这种合金的实例包括CoCrMo,CoFeCrMo和CoFeNiCrMo。 在一个具体实施方案中,合金是MP35N(CoNiCrMo),其可以是低钛(“低钛”)MP35N。 一根或多根这样的丝状物可以包括在线内。 该线可以由诸如铅,引线延伸或导管的可植入医疗设备携带。 导线可以将诸如连接器电极的元件电耦合到导电电极或传感器。
    • 4. 发明授权
    • Recombinant human interferon-like proteins
    • 重组人干扰素样蛋白
    • US08425895B2
    • 2013-04-23
    • US12665682
    • 2007-06-22
    • Haitao WangChunsheng MaoJizhi LiLing WangYong DuLongbin LiuJing XuRui Zhang
    • Haitao WangChunsheng MaoJizhi LiLing WangYong DuLongbin LiuJing XuRui Zhang
    • A61K38/21C07K14/00C08H1/02C12P21/04C07H21/04A61K38/00
    • C07K14/56A61K38/00C07K14/555
    • This application relates to recombinant human interferon-like proteins. In one embodiment a recombinant protein created by gene shuffling technology is described having enhanced anti-viral and anti-proliferative activities in comparison to naturally occurring human interferon alpha 2b (HuIFN-α2b). The invention encompasses a polynucleotide encoding the protein and recombinant vectors and host cells comprising the polynucleotide. Preferably the polynucleotide is selected from the group of polynucleotides each having a sequence at least 93% identical to SEQ ID: No. 1 and the protein is selected from the group of proteins each having an amino acid sequence at least 85% identical to SEQ ID NO: 2. The proteins and compositions comprising the proteins can be used for treatment of conditions responsive to interferon therapy, such as viral diseases and cancer.
    • 本申请涉及重组人类干扰素样蛋白。 在一个实施方案中,与天然存在的人干扰素α2b(HuIFN-α2b)相比,描述了通过基因改组技术产生的重组蛋白质具有增强的抗病毒和抗增殖活性。 本发明包括编码蛋白质的多核苷酸和包含多核苷酸的重组载体和宿主细胞。 优选地,多核苷酸选自各自具有与SEQ ID:No.1至少93%相同的序列的多核苷酸,并且所述蛋白质选自蛋白质组,其各自具有与SEQ ID NO:至少85%相同的氨基酸序列 包含蛋白质的蛋白质和组合物可用于治疗对干扰素治疗(例如病毒性疾病和癌症)有反应的病症。
    • 5. 发明授权
    • Serializer with odd gearing ratio
    • 具有奇数传动比的串行器
    • US08274412B1
    • 2012-09-25
    • US12987393
    • 2011-01-10
    • Fulong ZhangLing WangJohn Schadt
    • Fulong ZhangLing WangJohn Schadt
    • H03M9/00
    • H03M9/00
    • In certain embodiments of the invention, a serializer has (a) an initial, transfer stage that transfers incoming parallel data from a relatively slow timing domain to a relatively fast timing domain and (b) a final, serializing stage that converts the parallel data into serialized data. Between the transfer stage and the serializing stage is an update stage that (i) buffers data between the initial and final stages and (ii) can be used to toggle the serializer between an N−1 operating mode (that serializes (N−1) bits of parallel data) and an N+1 operating mode (that serializes (N+1) bits of parallel data) to achieve a net N:1 gearing ratio where N is an odd integer. The serializer can be configurable to support other gearing ratios as well.
    • 在本发明的某些实施例中,串行器具有(a)初始传送级,其将输入的并行数据从相对较慢的定时域传送到相对较快的定时域,以及(b)将并行数据转换成 序列化数据。 在转移阶段和序列化阶段之间是更新阶段,(i)缓冲初始阶段和最后阶段之间的数据,(ii)可用于在N-1操作模式(序列化(N-1) 并行数据的位)和N + 1工作模式(串行化并行数据的(N + 1)位),以实现净N:1的传动比,其中N是奇整数。 串行器可以配置为支持其他传动比。
    • 7. 发明授权
    • Recombinant human interferon-like proteins
    • 重组人干扰素样蛋白
    • US07625555B2
    • 2009-12-01
    • US11764786
    • 2007-06-18
    • Haitao WangChunsheng MaoJizhi LiJing XuRui ZhangLing WangYong DuLongbin Liu
    • Haitao WangChunsheng MaoJizhi LiJing XuRui ZhangLing WangYong DuLongbin Liu
    • A61K38/21C07K14/00C08H1/02C12P21/04C07H21/04A61K38/00
    • C07K14/56A61K38/00C07K14/555
    • This application relates to recombinant human interferon-like proteins. In one embodiment a recombinant protein created by gene shuffling technology is described having enhanced anti-viral and anti-proliferative activities in comparison to naturally occurring human interferon alpha 2b (HuIFN-α2b). The invention encompasses a polynucleotide encoding the protein and recombinant vectors and host cells comprising the polynucleotide. Preferably the polynucleotide is selected from the group of polynucleotides each having a sequence at least 93% identical to SEQ ID: No. 1 and the protein is selected from the group of proteins each having an amino acid sequence at least 85% identical to SEQ ID No: 2. The proteins and compositions comprising the proteins can be used for treatment of conditions responsive to interferon therapy, such as viral diseases and cancer.
    • 本申请涉及重组人类干扰素样蛋白。 在一个实施方案中,与天然存在的人干扰素α2b(HuIFN-α2b)相比,描述了通过基因改组技术产生的重组蛋白质具有增强的抗病毒和抗增殖活性。 本发明包括编码蛋白质的多核苷酸和包含多核苷酸的重组载体和宿主细胞。 优选地,多核苷酸选自各自具有与SEQ ID:No.1至少93%相同的序列的多核苷酸,并且所述蛋白质选自蛋白质组,其各自具有与SEQ ID NO:至少85%相同的氨基酸序列 否:2.包含蛋白质的蛋白质和组合物可用于治疗对干扰素治疗(例如病毒性疾病和癌症)有反应的病症。
    • 10. 发明申请
    • Closed Loop Cryosurgical System
    • 闭环冷冻手术系统
    • US20080114344A1
    • 2008-05-15
    • US11938898
    • 2007-11-13
    • Jia Hua XiaoLing Wang
    • Jia Hua XiaoLing Wang
    • A61B18/02
    • A61B18/02A61B2018/00041A61B2018/0262
    • A cryosurgical system and related methods of utilizing distinct freeze and thaw fluids to selectively freeze or thaw tissue as part of a cryosurgical treatment plan. A closed loop cryosurgical system can include a control console, a cryocooler, a freeze tank, a thaw tank as well as fluid supply and fluid return lines operably interconnecting one or more cryoprobes with the freeze and thaw tank. At the direction of the control console, the cryocooler is used to cool a freeze fluid in the freeze tank while a heating element in the thaw tank is used to head a thaw fluid in the thaw tank. By using distinctly controlled reservoirs of freeze and thaw fluid, the cryosurgical system is able to quickly cycle back and forth between freeze and thaw cycles conducted as part of a cryosurgical treatment.
    • 一种冷冻手术系统以及利用不同的冻融液选择性冻结或解冻组织的相关方法,作为冷冻治疗计划的一部分。 闭环冷冻手术系统可以包括控制台,低温冷冻机,冷冻罐,解冻槽以及将一个或多个冷冻探针与冷冻和解冻罐可操作地相互连接的流体供应和流体回流管线。 在控制台的方向,冷冻机用于冷却冷冻箱中的冻结流体,同时使用解冻罐中的加热元件来解冻解冻槽中的解冻液。 通过使用明确控制的冷冻和解冻液体储存器,冷冻手术系统能够在作为冷冻手术治疗的一部分进行的冷冻和解冻循环之间来回快速循环。